Page last updated: 2024-09-05

erlotinib hydrochloride and Thyroid Carcinoma, Anaplastic

erlotinib hydrochloride has been researched along with Thyroid Carcinoma, Anaplastic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Choi, YS; Jeon, MJ; Kim, TY; Kim, WB; Kim, WG; Kwon, H; Shong, YK; You, MH	1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Thyroid Carcinoma, Anaplastic

Article	Year
Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma. Endocrine-related cancer, 2022, 05-09, Volume: 29, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Mitogen-Activated Protein Kinase Kinases; Mutation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms	2022

Article

Year

Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma.

Endocrine-related cancer, 2022, 05-09, Volume: 29, Issue:6

Topics: Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Mitogen-Activated Protein Kinase Kinases; Mutation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms

2022